Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 52Gastrointestinal 42Genitourinary 17Breast 12Sarcoma 10Other solid neoplasm 10Gynecologic 10Tumor-Agnostic 9Head & Neck 8Dermatologic 7CNS 6Lymphoid 4Endocrine 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Neoplasm Metastasis 1Hematologic Neoplasms 1

Interventions

venetoclax 161Cytarabine 113Cyclophosphamide 106Azacitidine 103Specimen Handling 101fludarabine 89Biopsy 78Rituximab 52Daunorubicin 44Methotrexate 42fludarabine phosphate 39Vincristine 38Injections 37Decitabine 37Dexamethasone 36Magnetic Resonance Spectroscopy 34blinatumomab 31Granulocyte Colony-Stimulating Factor 30ibrutinib 28Idarubicin 28Whole-Body Irradiation 26Prednisone 26Doxorubicin 26Busulfan 26Mycophenolic Acid 25acalabrutinib 24Tacrolimus 23Melphalan 23Calcium Dobesilate 23obinutuzumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
atezolizumab × Other hematologic neoplasm × 90 days × Clear all
NCT02862275 2026-05-13

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
40 enrolled
Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡